Dyax, Defiante extend agreement to commercialize Kalbitor
In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.